VEDANTA BIOSCIENCES Cambridge, MA, USA
Direct-Acting Microbiome-based Therapeutic
Vedanta Biosciences is developing a novel class of therapies based on rationally-defined consortia of bacteria derived from the human microbiome. Focused on addressing immune and infectious diseases, Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture medicines based on live bacterial consortia. Vedanta’s lead program, VE303, is a rationally-defined bacterial consortia that colonizes the gut and safely outcompetes C. difficile, while reconstituting gut microbiota previously disrupted by antibiotic treatment. As a part of the CARB-X program, Vedanta will progress VE303 through the completion of Phase 1 clinical trials. Vedanta Biosciences is an affiliate of PureTech Health.
Current Development Stage: Phase I
CARB-X Investment: Initial investment of up to $5.4m.
Initial CARB-X Investment Date: October 1, 2017
Graduation Date: September 30, 2018